InvestorsHub Logo
Followers 127
Posts 7870
Boards Moderated 0
Alias Born 01/01/2011

Re: None

Sunday, 05/12/2013 10:21:04 PM

Sunday, May 12, 2013 10:21:04 PM

Post# of 143294
5/10/13 *Update Ticker Change? (It didn't open Friday though as we know guys, I hit up the company but didn't receive a response.)

BioAmber Inc.'s (BIOAU) initial public offering of 8 million units priced at $ 10 each, the low end of the estimated range.
Each unit consists of one share of common stock and one warrant to purchase half of one share of common stock. Each warrant will be exercisable at an exercise price of $11 per whole share of common stock.

The chemical company's units are expected to start trading Friday on the New York Stock Exchange under the symbol BIOAU.

Earlier this week, the company had cut its expected price for its IPO to between $10 and $12 from its prior view of $15 to $17.


BioAmber filed plans in November 2011 to raise up to $150 million through an IPO, planning to use proceeds to construct a facility in Ontario, Canada , among other purposes.

The company makes bio-succinic acid, which can be used to manufacture various everyday products, including plastics, food additives and personal-care products. The company has cast its bio-succinic acid as a low-cost alternative to petroleum-derived succinic acid.

The company has reported widening losses in the past three years. In 2012, BioAmber posted a loss of $39.5 million , compared with a year-earlier loss of $ 30.9 million.



=====================================================================

5/9/13 *Update

BioAmber Inc. Announces Pricing of Initial Public Offering
PR Newswire

MINNEAPOLIS, MN , May 9, 2013 /PRNewswire/ - BioAmber Inc. ("BioAmber") (NYSE: BIOAU), announced today the pricing of its initial public offering of 8,000,000 units consisting of one share of common stock and one warrant to purchase half of one share of common stock at $10 per unit, before underwriting discounts and commissions. Each warrant will be exercisable at an exercise price of $11.00 per whole share of common stock. All units are being sold by BioAmber.

BioAmber has granted the underwriters an option for 30 days to purchase up to an additional 1,200,000 units at the initial public offering price, less underwriting discounts and commissions, to cover over-allotments, if any. The units are expected to start trading on the New York Stock Exchange ("NYSE") under the symbol "BIOAU" on May 10, 2013 . The common stock and warrants comprising the units will begin trading separately on NYSE under the symbols " BIOA" and "BIOAWS", respectively, on the first trading day following the expiration of the underwriters' 30-day over-allotment option, at which time trading of the units will be suspended and the units will be delisted.

BioAmber also intends to list its common stock on the Professional Segment of the regulated market of NYSE Euronext in Paris under the symbol "BIOA." This offering is expected to close on May 14, 2013.

Credit Suisse, Barclays, and Société Générale are acting as joint book-running managers for the offering. Pacific Crest Securities is acting as co-manager for the offering.

A registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission on May 9, 2013 . This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering of these securities is being made only by means of a prospectus, copies of which may be obtained from Credit Suisse Securities (USA) LLC by mail at One Madison Avenue , New York, New York 10010, Attention: Prospectus Department, or by calling toll free (800) 221-1037, or by emailing newyork.prospectus@credit-suisse.com.
About BioAmber Inc.

BioAmber is a next generation chemicals company. Its proprietary technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into chemicals including succinic acid and 1,4-butanediol, which are used in a wide variety of everyday products such as plastics, food additives and personal care products. For more information visit the company's web site at: www.bio-amber.com


.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.